Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
about
Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.AIDS Clinical Research in Spain-Large HIV Population, Geniality of Doctors, and Missing Opportunities.
P2860
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@en
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@nl
type
label
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@en
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@nl
prefLabel
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@en
Impact of switching from zidov ...... lipoatrophy: the RECOMB study.
@nl
P2093
P2860
P50
P356
P1433
P1476
Impact of switching from zidov ...... lipoatrophy: the RECOMB study
@en
P2093
E Martínez
J Berenguer
M L Alvarez
M Larrousse
S Arterburn
P2860
P304
P356
10.1111/HIV.12011
P577
2013-01-09T00:00:00Z